Style | Citing Format |
---|---|
MLA | Asgari T, et al.. "Keratitis-Ichthyosis-Deafness Syndrome: Phenotypic Heterogeneity and Treatment Perspective of Patients With P.Asp50asn Gjb2 Mutation." Dermatologic Therapy, vol. 33, no. 6, 2020, pp. -. |
APA | Asgari T, Naji M, Mansouri P, Mahmoudi H, Zabihi M, Youssefian L, Mahdavi M, Naraghi ZS, Zeinali S, Vahidnezhad H, Uitto J (2020). Keratitis-Ichthyosis-Deafness Syndrome: Phenotypic Heterogeneity and Treatment Perspective of Patients With P.Asp50asn Gjb2 Mutation. Dermatologic Therapy, 33(6), -. |
Chicago | Asgari T, Naji M, Mansouri P, Mahmoudi H, Zabihi M, Youssefian L, Mahdavi M, et al.. "Keratitis-Ichthyosis-Deafness Syndrome: Phenotypic Heterogeneity and Treatment Perspective of Patients With P.Asp50asn Gjb2 Mutation." Dermatologic Therapy 33, no. 6 (2020): -. |
Harvard | Asgari T et al. (2020) 'Keratitis-Ichthyosis-Deafness Syndrome: Phenotypic Heterogeneity and Treatment Perspective of Patients With P.Asp50asn Gjb2 Mutation', Dermatologic Therapy, 33(6), pp. -. |
Vancouver | Asgari T, Naji M, Mansouri P, Mahmoudi H, Zabihi M, Youssefian L, et al.. Keratitis-Ichthyosis-Deafness Syndrome: Phenotypic Heterogeneity and Treatment Perspective of Patients With P.Asp50asn Gjb2 Mutation. Dermatologic Therapy. 2020;33(6):-. |
BibTex | @article{ author = {Asgari T and Naji M and Mansouri P and Mahmoudi H and Zabihi M and Youssefian L and Mahdavi M and Naraghi ZS and Zeinali S and Vahidnezhad H and Uitto J}, title = {Keratitis-Ichthyosis-Deafness Syndrome: Phenotypic Heterogeneity and Treatment Perspective of Patients With P.Asp50asn Gjb2 Mutation}, journal = {Dermatologic Therapy}, volume = {33}, number = {6}, pages = {-}, year = {2020} } |
RIS | TY - JOUR AU - Asgari T AU - Naji M AU - Mansouri P AU - Mahmoudi H AU - Zabihi M AU - Youssefian L AU - Mahdavi M AU - Naraghi ZS AU - Zeinali S AU - Vahidnezhad H AU - Uitto J TI - Keratitis-Ichthyosis-Deafness Syndrome: Phenotypic Heterogeneity and Treatment Perspective of Patients With P.Asp50asn Gjb2 Mutation JO - Dermatologic Therapy VL - 33 IS - 6 SP - EP - PY - 2020 ER - |